Enhanced delivery system of flutamide loaded chitosan-dextran sulphate nanoparticles for prostate cancer

Journal of Biomedical Nanotechnology

Volumn 9, Issue 3, 2013, Pages 335-347

  Anitha, A ^a   Uthaman, Saji ^a   Nair, Shantikumar V ^a   Jayakumar, R ^a   Lakshmanan, Vinoth Kumar ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti Androgen; Cancer Drug Delivery; Chitosan; Dextran Sulphate; Flutamide; Nanoparticles; Prostate Cancer

Indexed keywords

ANTI-ANDROGEN; CANCER DRUG DELIVERIES; DEXTRAN SULPHATE; FLUTAMIDE; PROSTATE CANCERS;

CELL CULTURE; CELL DEATH; CHITOSAN; DEXTRAN; DISEASES; DRUG DELIVERY; FLOW CYTOMETRY; SULFUR COMPOUNDS;

NANOPARTICLES;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHITOSAN DERIVATIVE; DEXTRAN SULFATE; FLUTAMIDE; LACTATE DEHYDROGENASE; NANOPARTICLE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLOOD COMPATIBILITY; CANCER CELL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; MALE; MOLECULAR IMAGING; NONHUMAN; PARTICLE SIZE; PH; PROSTATE CANCER;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CHITOSAN; DEXTRANS; DRUG DELIVERY SYSTEMS; FLUTAMIDE; HUMANS; LIGHT; MALE; MATERIALS TESTING; MICE; NANOPARTICLES; PARTICLE SIZE; PROSTATIC NEOPLASMS; RHODAMINE 123; SCATTERING, RADIATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; WHOLE BLOOD COAGULATION TIME;

EID: 84876569930     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1558     Document Type: Article

References (61)

1. J. Naitoh, R. L. Zeiner, and J. B. Dekernion, Diagnosis and treatment of prostate cancer. Am. Fam. Physician. 57, 1531 (1998).
2. H. Bu, S. Bormann, G. Schafer, W. Horninger, P. Massoner, A. Neeb, V. K. Lakshmanan, D. Maddalo, A. Nestl, H. S. ltmann, A. C. B. Cato, and H. Klocker, The anterior gradient 2 (AGR2) gene is over expressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. The Prostate 75, 715 (2011).
3. F. Labrie, A. Dupont, and A. Belanger, Complete androgen blockade for the treatment of prostate cancer. Important Adv. Oncol. 12, 193 (1985).
4. F. Labrie, Endocrine therapy for prostate cancer. Endocrinol. Metab. Clin. North. Am. 20, 845 (1991).
5. F. Labrie, Mechanism of action and pure androgenic properties of flutamide. Cancer 72, 3816 (1993).
6. G. Monfete, A. Dupont, and F. Labrie, Temporary combination therapy with flutamide and tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, edited by F. Labrie, Elsevier Science Publishers, New York (1989), pp. 41-51.
7. R. Neri, Pharmacology and pharmacokinetics of flutamide. Urology 34, 19 (1989).
8. 2 in vitro model. J. Pharm. Pharm. Sci. 3, 220 (2000).
9. V. K. Lakshmanan, K. S. Snima, J. D. Bumgardner, S. V. Nair, and R. Jayakumar, Chitosan-based nanoparticles in cancer therapy. Adv. Polym. Sci. 243, 55 (2011).
10. S. Uthaman, K. S. Snima, M. Annapoorna, K. C. Ravindranath, S. V. Nair, and V. K. Lakshmanan, Novel boswellic acids nanoparticles induces cell death in prostate cancer cells. J. Nat. Prod. 5, 100 (2012).
11. G. Renu, V. V. Divya Rani, S. V. Nair, K. R. V. Subramanian, and V. K. Lakshmanan, Development of cerium oxide nanoparticles and its cytotoxicity in prostate cancer cells. Adv. Sci. Lett. 5, 1 (2012).
12. J. A. J. Nesalin, K. Gowthamarajan, and C. N. Somashekhara, Formulation and evaluation of nanoparticles containing flutamide. Int J. Chem. Tech. Res. 1, 1331 (2009).
13. K. Umasankar and C. U. M. Reddy, Nanoparticular drug delivery system of anticancer drug-flutamide. Int. J. Pharm. Tech. Res. 2, 1155 (2010).
14. N. Elgindy, K. Elkhodairy, A. Molokhia, and A. Elzoghby, Biopolymeric microparticles combined with lyophilized monophase dispersions for controlled flutamide release. Int. J. Pharm. 411, 113 (2011).
15. P. A. Palumbo, P. G. P. Andrea, T. Daniela, P. Pasquale, B. Silvestre, and G. Gaetano, Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of flutamide. J. Drug Target 20, 433 (2012).
16. G. Pitarresi, T. Daniela, G. Mario, C. Fiorica, F. Calascibetta, and G.Gaetano, Inulin-based hydrogel for oral delivery of flutamide: Preparation, characterization, and in vivo release studies. Macromol. Biosci. 12, 770 (2012).
17. R. Jayakumar, M. Prabaharan, R. L. Reis, and J. F. Mano, Graft copolymerized chitosan-present status and applications. Carbohydr. Polym. 62, 158 (2005).
18. A. Anitha, V. V. Divyarani, R. Krishna, V. Sreeja, N. Selvamurugan, S. V. Nair, H. Tamura, and R. Jayakumar, Synthesis, characterization, cytotoxicity and antibacterial studies of chitosan, O-carboxymethyl and N,O-carboxymethyl chitosan nanoparticles. Carbohydr. Polym. 78, 677 (2009).
19. A. Anitha, N. Deepa, K. P. Chennazhi, S. V. Nair, H. Tamura, and R. Jayakumar, Development of mucoadhesive thiolated chitosan nanoparticles for biomedical applications. Carbohydr. Polym. 83, 73 (2011).
20. R. Jayakumar, M. Prabaharan, S. V. Nair, and H. Tamura, Novel chitin and chitosan nanofibers in biomedical applications. Biotechnol. Adv. 28, 150 (2010).
21. T. A. Khan, K. Peh, and H. Chng, Mechanical, bioadhesive strength and biological evaluations of chitosan films for wound dressing. J. Pharm. Pharm. Sci. 3, 311 (2000).
22. E. I. Rabea, M. E. Badawy, C. V. Stevens, G. Smagghe, and W. Steubaut, Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 4, 1465 (2003).
23. A. Dev, N. S. Binulal, A. Anitha, S. V. Nair, T. Furuike, H. Tamura, and R. Jayakumar, Preparation of poly(lactic acid)/chitosan nanoparticles for anti-HIV drug delivery applications. Carbohydr. Polym. 80, 838 (2010).
24. E. M. Mathew, C. M. Jithin, K. Manzoor, S. V. Nair, H. Tamura, and R. Jayakumar, Folate conjugated carboxymethyl chitosanmanganese doped zinc sulphide nanoparticles for targeted drug delivery and imaging of cancer cells. Carbohydr. Polym. 80, 448 (2010).
25. N. Csaba, M. Koping-Hoggard, and M. J. Alonso, Ionically cross linked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int. J. Pharm. 382, 214 (2009).
26. A. Dev, J. C. Mohan, V. Sreeja, H. Tamura, G. R. Patzke, F. Hussain, S. Weyeneth, S. V. Nair, and R. Jayakumar, Novel carboxymethyl chitin nanoparticles for cancer drug delivery applications. Carbohydr. Polym. 79, 1079 (2010).
27. E. Khor and L. Y. Lim, Implantable applications of chitin and chitosan. Biomaterials 24, 2349 (2003).
28. M. Peter, N. S. Binulal, S. Soumya, S. V. Nair, T. Furuike, H. Tamura, and R. Jayakumar, Nanocomposites of bioactive glass ceramic nanoparticles disseminated chitosan matrix for tissue engineering applications. Carbohydr. Polym. 79, 289 (2010).
29. M. Peter, N. S. Binulal, S. V. Nair, N. Selvamurugan, H. Tamura, and R. Jayakumar, Novel biodegradable chitosan-gelatin/nano-bioactive glass ceramic composite scaffolds for alveolar bone tissue engineering. Chem. Eng. J. 158, 361 (2010).
30. P. T. Sudheesh Kumar, V. K. Lakshmanan, R. Mincy, R. Biswas, H. Tamura, S. V. Nair, and R. Jayakumar, Evaluation of wound healing potential of ß-chitin hydrogel/nano zinc oxide composite bandage. Pharm Res. (2012), DOI 10.1007/s11095-012-0898-y.
31. R. Jayakumar, M. Prabaharan, S. V. Nair, and H. Tamura, Novel chitin and chitosan nanofibers in biomedical applications. Biotechnol. Adv. 28, 150 (2010).
32. P. T. Sudheesh Kumar, V. K. Lakshmanan, T. V. Anilkumar, C. Ramya, P. Reshmi, A. G. Unnikrishnan, S. V. Nair, and R. Jayakumar, Flexible and microporous chitosan hydrogel/nano ZnO composite bandages for wound dressing: In vitro and in vivo evaluation. ACS Appl. Mater. Interfaces 4, 2618 (2012).
33. P. T. Sudheesh Kumar, V. K. Lakshmanan, R. Biswas, Shantikumar V. Nair, and R. Jayakumar, Synthesis and biological evaluation of chitin hydrogel/nano ZnO composite bandage as antibacterial wound dressing. J. Biomed. Nanotechnol. 8, 1 (2012).
34. Y. H. Jin, H. Y. Hu, M. X. Qiao, J. Zhu, J. W. Qi, C. J. Hu, Q. Zhang, and D. W. Chen, pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation. Colloids Surf. B 94, 184 (2012).
35. J. H. Kim, Y. S. Kim, K. Park, E. Kang, S. Lee, H. Y. Nam, K. Kim, J. H. Park, D. Y. Chi, R. W. Park, I. S. Kim, K. Choi, and I. C. Kwon, Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 29, 1920 (2008).
36. M. Rajam, S. Pulavendran, C. Rose, and A. B. Mandal, Chitosan nanoparticles as a dual growth factor delivery system for tissue engineering applications. Int. J. Pharm. 410, 145 (2011).
37. J. H. Kim, Y. S. Kim, S. Kim, J. H. Park, K. Kim, K. Choi, H. Chung, S. Y. Jeong, R. W. Park, I. S. Kim, and I. C. Kwon, Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Controlled Release 111, 228 (2006).
38. K. H. Min, K. Park, Y. S. Kim, S. M. Bae, S. Lee, H. G. Jo, R. W. Park, I. S. Kim, S. Y. Jeong, K. Kim, and I. C. Kwon, Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Controlled Release 127, 208 (2008).
39. A. Anitha, V. G. Deepagan, V. V. Divya Rani, M. Deepthy, S. V. Nair, and R. Jayakumar, Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphatechitosan nanoparticles. Carbohydr. Polym. 84, 1158 (2011).
40. D. Guzey and J. McClements, Formation, stability and properties of multilayer emulsions for application in the food industry. Adv. Colloid. Interface Sci. 128, 227 (2006).
41. W. Tiyaboonchai and N. Limpeanchob, Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int. J. Pharm. 329, 142 (2007).
42. M. L. Tan, A. M. Friedhuber, D. E. Dunstan, P. F. M. Choong, and C. R. Dass, The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 31, 541 (2010).
43. M. R. Saboktakin, R. M. Tabatabaie, A. Maharramov, and M. A. Ramazanov, Synthesis and characterization of superparamagnetic chitosan-dextran sulfate hydrogels as nano carriers for colonspecific drug delivery. Carbohydr. Polym. 81, 372 (2010).
44. M. R. Saboktakin, R. M. Tabatabaie, A. Maharramov, and M. A. Ramazanov, Synthesis and characterization of pH-dependent glycol chitosan and dextran sulfate nanoparticles for effective brain cancer treatment. Int. J. Biol. Macromol. 49, 747 (2011).
45. A. Anitha, S. Maya, N. Deepa, K. P. Chennazhi, S. V. Nair, H. Tamura, and R. Jayakumar, Efficient water soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells. Carbohydr. Polym. 83, 452 (2011).
46. S. B. Rao and C. P. Sharma, Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential. J. Biomed. Mater. Res. 34, 28 (1997).
47. V. B. Morris and C. P. Sharma, Folate mediated in vitro targeting of depolymerised trimethylated chitosan having arginine functionality. J. Colloid Interface Sci. 348, 360 (2010).
48. M. Harboe, A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand. J. Clin. Lab. Invest. 11, 66 (1959).
49. A. Anitha, K. P. Chennazhi, S. V. Nair, and R. Jayakumar, 5-Flourouracil loaded N,O-carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer. J. Biomed. Nanotechnol. 8, 1 (2012).
50. E. Bilensoy, C. S. Guneşs E. Kin, A. L. Dogan, Y. Aktas, M. Sen, and N. A. Mungan, Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors. Int. J. Pharm. 371, 170 (2009).
51. A. Anitha, S. Maya, N. Deepa, K. P. Chennazhi, S. V. Nair, and R. Jayakumar, Curcumin-loaded N,O-Carboxymethyl chitosan nanoparticles for cancer drug delivery. J. Biomater. Sci. 23, 1381 (2012).
52. Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387 (1986).
53. C. Laye, D. J. McClements, and J. Weiss, Formation of biopolymercoated liposomes by electrostatic deposition of chitosan. J. Food Sci. 73, 7 (2008).
54. N. Elgindy, K. Elkhodairy, A. Molokhia, and A. Elzoghby, Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug flutamide. Eur. J. Pharm. Biopharm. 74, 397 (2009).
55. T. Kean and M. Thanou, Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv Rev. 62, 3 (2010).
56. D. G. Kim, Y. I. Jeong, C. Choi, S. H. Roh, S. K. Kang, M. K. Jang, and J. W. Nah, Retinol-encapsulated low molecular water-soluble chitosan nanoparticles. Int. J. Pharm. 319, 130 (2006).
57. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain, Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Nat. Acad. Sci. USA 95, 4607 (1998).
58. R. Jayakumar, R. L. Reis, and J. F. Mano, Synthesis and characterization of pH-sensitive thiol-containing chitosan beads for controlled drug delivery applications. Drug Deliv. 14, 9 (2007).
59. D. Sinha, F. S. Seaman, and P. N. Walsh, Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX. Biochemistry 26, 3768 (1987).
60. F. A. Saeedi, Effects of flutamide on [Methyl-3H]-choline uptake in human prostate cancer-3 cells: A pilot study. Curr. Ther. Res. 68, 226 (2007).
61. G. Sufrin and D. S. Coffey, Flutamide, mechanism of action of a new non-steroidal antiandrogen. Invest. Urol. 13, 429 (1976).